News

How HIV spreads from DCs
Enlarge image

ResearchSpainSwitzerlandGermany

How HIV spreads from DCs

20.12.2012 - Spanish researchers have unraveled how HIV disperses throughout the body – and can block the process before it occurs.

In a previous publication with Swiss and German virologists, researchers headed by Nuria Izquierdo-Useros from the AIDS Research Institute IrsiCaixa in Barcelona discovered that the HI virus uses specific membrane lipids called gangliosides on their surface to enter dendritic cells (DCs) by modifying membrane fluidity. Based on these findings, they tried to make the DC’s membrane more rigid by using a dihydroceramide desaturase (Des-1) blocker, which they have filed for patent. The new approach seems promising because HIV has first to enter DCs to be passed to their target cells, the CD4 T lymphocytes, in a process termed trans-infection. Now, the Spanish team has identified the molecule on the surface of DCs that recognises and binds the gangliosides and allows HIV to be taken up by dendritic cells and transmitted to CD4 cells. The new study is published in the open access journal PLOS Biology.

In order to identify the precise molecule located on the membrane of the dendritic cells capable of capturing HIV, the researchers studied one family of proteins that are present on the surface of these cells, called Siglecs. It is known that these proteins bind to the gangliosides on the HIV surface. In the laboratory, they mixed the virus with dendritic cells that displayed different quantities of Siglec-1, and found that a higher quantity of Siglec-1 led to those dendritic cells capturing more HIV, which in turn allowed for enhanced transmission of HIV to CD4 T lymphocytes, a process called trans-infection.

The team then tried inhibiting the Siglec-1 protein. They found that the dendritic cells lost their capacity to capture HIV and, importantly, they also lost their ability to transfer HIV to CD4 T lymphocytes. With all these data, the scientists concluded that Siglec-1 is the molecule responsible for HIV entrance into the dendritic cells, and could therefore become a new therapeutic target. "We had the key and now we have found a lock," explains Javier Martínez-Picado. "Now we are already working on the development of a drug that could block this process to improve the efficacy of the current existing treatments against AIDS".

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/how-hiv-spreads-from-dcs.html

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

M&ASwitzerland

09.06.2015 Monsanto plans to acquire Syngenta AG, but seems reluctant to dig deep into its pockets. The Swiss crop chemical maker has now rejected the second offer from the US company.

InnovationPolandEU

05.06.2015 Polish drug maker Polpharma has received a €45m loan from the European Investment Bank to further its biosimilar research. The operation is part of InnovFin, a new programme set up to support innovative research.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOCUTIS (UK)0.22 GBP15.79%
  • ADOCIA (F)68.80 EUR9.21%
  • WILEX (D)3.90 EUR8.94%

FLOP

  • SANTHERA (CH)89.00 CHF-5.82%
  • OXFORD BIOMEDICA (UK)9.15 GBP-5.67%
  • NEUROVIVE PHARMACEUTICAL AB (S)21.90 SEK-5.19%

TOP

  • PROTHENA PLC (IE)51.28 USD30.0%
  • DBV Technologies (F)52.65 EUR22.4%
  • BIOINVENT INTERNATIONAL AB (S)2.61 SEK17.0%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)21.90 SEK-54.2%
  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • CELLECTIS (F)31.83 EUR-22.2%

TOP

  • ADOCIA (F)68.80 EUR386.2%
  • WILEX (D)3.90 EUR358.8%
  • 4SC (D)4.39 EUR352.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • ACTIVE BIOTECH (S)9.00 SEK-69.6%
  • NEOVACS (F)1.19 EUR-67.5%

No liability assumed, Date: 29.06.2015